Top

Published in:

01-04-2014 | Research

Ephrin Receptor (Eph) -A1, -A2, -A4 and -A7 Expression in Mobile Tongue Squamous Cell Carcinoma: Associations with Clinicopathological Parameters and Patients Survival

Authors: Stamatios Theocharis, Jerzy Klijanienko, Constantinos Giaginis, Paraskevi Alexandrou, Efstratios Patsouris, Xavier Sastre-Garau

Published in: Pathology & Oncology Research | Issue 2/2014

Abstract

Ephrin receptors (Ephs) are frequently overexpressed in a wide variety of human malignant tumors, being associated with tumor growth, invasion, metastasis and angiogenesis. The present study aimed to evaluate the clinical significance of Eph-A1, -A2, -A4 and -A7 protein expression in mobile tongue squamous cell carcinoma (SCC). Eph-A1, -A2, -A4 and -A7 protein expression was assessed immunohistochemically on 37 mobile tongue SCC tissue samples and was analyzed in relation with clinicopathological characteristics, overall and disease-free patients’ survival. All the examined mobile tongue SCC cases were found positive for Eph-A1, -A2, -A4 and -A7. Significant associations were noted between high Eph-A1, -A4 and -A7 expression and absence of lymph node metastases (p = 0.0263, p = 0.0461 and p = 0.0461, respectively). High Eph-A1, -A2 and -A7 expression was significantly more frequently observed in patients presenting absence of vascular invasion (p = 0.0444), dense stromal inflammatory reaction (p = 0.0063) and female gender (p = 0.0327), respectively. Mobile tongue SCC patients with high Eph-A7 expression presented longer overall and disease-free survival compared to those with low Eph-A7 expression (log-rank test, p = 0.0093 and p = 0.0164, respectively). In multivariate analysis, Eph-A7 expression was identified as independent prognostic factor of overall survival (Cox-regression analysis, p = 0.0426). The present study supported evidence that Ephs may participate in the malignant transformation of mobile tongue SCC, reinforcing their utility as clinical markers for patients’ management and prognosis, as also as targets for potential therapeutic intervention in tongue chemoprevention.

Zhang J, Hughes SE (2006) Role of the ephrin and Ephrin receptor tyrosine kinase families in angiogenesis and development of the cardiovascular system. J Pathol 208:453–461PubMedCrossRef

Pasquale EB (2008) Eph-ephrin bidirectional signaling in physiology and disease. Cell 133:38–52PubMedCrossRef

Nakamoto M, Bergemann AD (2002) Diverse role for the Eph family of receptor tyrosine kinases in carcinogenesis. Microsc Res Tech 59:58–67PubMedCrossRef

Surawska H, Ma PC, Salgia R (2004) The role of ephrins and Eph receptors in cancer. Cytokine Growth Factor Rev 15:419–433PubMedCrossRef

Cheng N, Brantley DM, Chen J (2002) The ephrins and Eph receptors in angiogenesis. Cytokine Growth Factor Rev 13:75–85PubMedCrossRef

Brandley-Sieders DM, Chen J (2007) Eph receptor tyrosine kinase in angiogenesis: from development to disease. Angiogenesis 7:17–28CrossRef

Castaño J, Davalos V, Schwartz S Jr, Arango D (2008) EPH receptors in cancer. Histol Histopathol 23:1011–1023PubMed

Ireton RC, Chen J (2005) EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics. Curr Cancer Drug Targets 5:149–157PubMedCrossRef

Brantley-Sieders D, Schmidt S, Parker M, Chen J (2004) Eph receptor tyrosine kinases in tumor and tumor microenvironment. Curr Pharm Des 10:3431–3442PubMedCrossRef

10.

Heroult M, Schaffner F, Augustin HG (2004) Eph receptor and ephrin ligand-mediated interactions during angiogenesis and tumor progression. Exp Cell Res 312:642–650CrossRef

11.

Canto MT, Devesa SS (2002) Oral cavity and pharynx cancer incidence in the United States, 1975–1988. Oral Oncol 38:610–617PubMedCrossRef

12.

Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics. CA Cancer J Clin 57:43–66PubMedCrossRef

13.

Brenner H (2002) Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysis. Lancet 360:1131–1135PubMedCrossRef

14.

Shiboski CH, Schmidt BL, Jordan RC (2005) Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20–44 years. Cancer 103:1843–1849PubMedCrossRef

15.

Sano D, Myers JN (2007) Metastasis of squamous cell carcinoma of the oral tongue. Cancer Metastasis Rev 26:645–662PubMedCrossRef

16.

Kantola S, Parikka M, Jokinen K et al (2000) Prognostic factors in tongue cancer-relative importance of demographic, clinical and histopathological factors. Br J Cancer 83:614–619PubMedCentralPubMedCrossRef

17.

Wangsa D, Ryott M, Avall-Lundquist E et al (2008) Ki-67 expression predicts locoregional recurrence in stage I oral tongue carcinoma. Br J Cancer 99:1121–1128PubMedCentralPubMedCrossRef

18.

Giaginis C, Tsourouflis G, Zizi-Serbetzoglou A, Kouraklis G, Chatzopoulou E, Theocharis S (2010) Clinical significance of Ephrin (Eph)-A1, -A2, -A4, -A5 and -A7 receptors in pancreatic ductal adenocarcinoma. Pathol Oncol Res 16:267–276PubMedCrossRef

19.

Karidis NP, Giaginis C, Tsourouflis G, Alexandrou P, Delladetsima I, Theocharis S (2011) Eph-A2 and Eph-A4 expression in human benign and malignant thyroid lesions: an immunohistochemical study. Med Sci Monit 17:BR257–BR265PubMedCentralPubMedCrossRef

20.

Brandwein-Gensler M, Teixeira MS, Lewis CM et al (2005) Oral squamous cell carcinoma: histological risk assessment, but not margin status, is strongly predictive of local disease-free and overall survival. Am J Surg Pathol 29:167–178PubMedCrossRef

21.

Shintani S, Matsura H, Hasegawa Y, Nakayama B, Fujimoto Y (1997) The relationship of shape of tumor invasion to depth of invasion and cervical lymph node metastasis in squamous cell carcinoma of the tongue. Oncology 54:463–467PubMedCrossRef

22.

Barnes L, Eveson JW, Reichert P, Sidransky D (2005) World Health Organization classifications tumours. Pathology and genetics of head and neck tumours. IARC Press, Lyon

23.

Po Wing Yen A, Lam KY, Lam LK et al (2002) Prognostic factors clinically stage I and II oral tongue carcinoma: a comparative study of stage, thickness, shape, growth pattern, invasive front malignancy grading, Martinez-Gimeno score and pathologic features. Head Neck 24:513–520CrossRef

24.

Klijanienko J, el-Naggar AK, de Braud F (1995) Tumor vascularization, mitotic index, histopathologic grade, and DNA ploidy in the assessment of 114 head and neck squamous cell carcinomas. Cancer 75:1649–1656PubMedCrossRef

25.

Theocharis S, Klijanienko J, Giaginis C et al (2011) Histone deacetylase (HDAC)-1 and −2 expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival. J Oral Med Pathol 40:706–714CrossRef

26.

Theocharis S, Klijanienko J, Giaginis C et al (2011) Metallothionein expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival. Histopathology 59:514–525PubMedCrossRef

27.

Dong Y, Wang J, Sheng Z et al (2009) Downregulation of EphA1 in colorectal carcinomas correlates with invasion and metastasis. Mod Pathol 22:151–160PubMedCrossRef

28.

Saito T, Masuda N, Miyazaki T et al (2004) Expression of EphA2 and E-cadherin in colorectal cancer: correlation with cancer metastasis. Oncol Rep 11:605–611PubMed

29.

Abraham S, Knapp DW, Cheng L et al (2006) Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder. Clin Cancer Res 12:353–360PubMedCrossRef

30.

Holm R, Knopp S, Suo Z, Tropè C, Nesland JM (2007) Expression of EphA2 and EphrinA-1 in vulvar carcinomas and its relation to prognosis. J Clin Pathol 60:1086–1091PubMedCentralPubMedCrossRef

31.

Hafner C, Becker B, Landthaler M, Vogt T (2006) Expression profile of Eph receptors and ephrin ligands in human skin and downregulation of EphA1 in nonmelanoma skin cancer. Mod Pathol 19:1369–1377PubMedCrossRef

32.

Lin YG, Han LY, Kamat AA et al (2007) EphA2 overexpression is associated with angiogenesis in ovarian cancer. Cancer 109:332–340PubMedCrossRef

33.

Yuan W, Chen Z, Wu S et al (2009) Expression of EphA2 and E-cadherin in Gastric Cancer: correlated with Tumor Progression and Lymphogenous Metastasis. Pathol Oncol Res 15:473–478PubMedCrossRef

34.

Zeng G, Hu Z, Kinch MS et al (2003) High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia. Am J Pathol 163:2271–2276PubMedCentralPubMedCrossRef

35.

Kinch MS, Moore MB, Harpole DH (2003) Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin Cancer Res 9:613–618PubMed

36.

Shao Z, Zhang WF, Chen XM, Shang ZJ (2008) Expression of EphA2 and VEGF in squamous cell carcinoma of the tongue: correlation with the angiogenesis and clinical outcome. Oral Oncol 44:1110–1117PubMedCrossRef

37.

Kamat AA, Coffey D, Merritt WM et al (2009) EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer. Cancer 115:2684–2692PubMedCentralPubMedCrossRef

38.

Miyazaki T, Kato H, Fukuchi M, Nakajima M, Kuwano H (2003) EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma. Int J Cancer 103:657–663PubMedCrossRef

39.

Wang LF, Fokas E, Bieker M et al (2008) Increased expression of EphA2 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients. Oncol Rep 19:151–156PubMed

40.

Herrem CJ, Tatsumi T, Olson KS et al (2005) Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma. Clin Cancer Res 11:226–231PubMed

41.

Oki M, Yamamoto H, Taniguchi H, Adachi Y, Imai K, Shinomura Y (2008) Overexpression of the receptor tyrosine kinase EphA4 in human gastric cancers. World J Gastroenterol 14:5650–5656PubMedCentralPubMedCrossRef

42.

Wang LF, Fokas E, Juricko J et al (2008) Increased expression of EphA7 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients. BMC Cancer 8:79PubMedCentralPubMedCrossRef

43.

Pasquale EB (2010) Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer 10:165–180PubMedCentralPubMedCrossRef

44.

Tandon M, Vemula SV, Mittal SK (2011) Emerging strategies for EphA2 receptor targeting for cancer therapeutics. Expert Opin Ther Targets 15:31–51PubMedCentralPubMedCrossRef

45.

Landen CN Jr, Chavez-Reyes A, Bucana C et al (2005) Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 65:6910–6918PubMedCrossRef

46.

Shahzad MM, Lu C, Lee JW et al (2009) Dual targeting of EphA2 and FAK in ovarian carcinoma. Cancer Biol Ther 8:1027–1034PubMedCentralPubMedCrossRef

47.

Zhuang G, Brantley-Sieders DM, Vaught D et al (2010) Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. Cancer Res 70:299–308PubMedCrossRef

Title: Ephrin Receptor (Eph) -A1, -A2, -A4 and -A7 Expression in Mobile Tongue Squamous Cell Carcinoma: Associations with Clinicopathological Parameters and Patients Survival
Authors: Stamatios Theocharis
Jerzy Klijanienko
Constantinos Giaginis
Paraskevi Alexandrou
Efstratios Patsouris
Xavier Sastre-Garau
Publication date: 01-04-2014
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 2/2014
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-013-9692-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2014

Evaluation of the Accuracy of Preoperative MRI in Measuring Myometrial Infiltration in Endometrial Carcinoma

Squamous Cell/Adenosquamous Carcinomas and Adenocarcinomas of the Gallbladder: An Immunohistochemistry Study of Prognostic Markers

Fas Gene Variants in Childhood Acute Lymphoblastic Leukemia and Association with Prognosis

Identification of Differentially Coexpressed Genes in Gonadotrope Tumors and Normal Pituitary Using Bioinformatics Methods

Over-Expression of Cancerous Inhibitor of PP2A (CIP2A) in Bone Marrow Cells from Patients with a Group of High-Risk Myelodysplastic Syndromes

Trastuzumab-Induced Systemic Capillary Leak Syndrome in a Breast Cancer Patient

Keynote webinar | Spotlight on antibody–drug conjugates in cancer